Compare HYPR & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HYPR | IFRX |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.9M | 60.6M |
| IPO Year | 2021 | 2017 |
| Metric | HYPR | IFRX |
|---|---|---|
| Price | $1.18 | $0.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $1.28 | ★ $8.50 |
| AVG Volume (30 Days) | ★ 291.7K | 178.8K |
| Earning Date | 04-20-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.68 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,890,000.00 | N/A |
| Revenue This Year | $5.96 | N/A |
| Revenue Next Year | $34.43 | $1,054.36 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.84 | N/A |
| 52 Week Low | $0.53 | $0.71 |
| 52 Week High | $2.22 | $1.94 |
| Indicator | HYPR | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.14 | 56.15 |
| Support Level | $1.04 | $0.96 |
| Resistance Level | $1.19 | $1.16 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 68.29 | 82.45 |
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.